← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCPhase 2
Cytoxan (Cytoxan)
Merck Sharp & Dohme LLC·Metastatic Breast Cancer
ORR 95%
Overview
Program
Cytoxan
Overview
Company
Merck Sharp & Dohme LLC
Overview
Modality
ADC
Overview
Target
Metastatic Breast Cancer
Overview
Indication
Multiple Myeloma, Refractory
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Mechanism
targeted metabolomics analysis based on UPLC-MS/MS and a reverse transcription polymerase chain reaction (RT-qPCR) technology were used to explore the specific metabolic pathway
MoA
Biomarker
EGFR gene exhibited the high
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
PK
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment of patients with nonmalignant or malignant blood disorders. Its success has been limited by graft-versus-host disease (GVHD). Current systemic nontargeted conditioning regi…
Toxicology
CRS
grade 4
Clinical
Primary efficacy
ORR 95%
Clinical
ORR
95.0%
Clinical
Result source
ClinicalTrials.gov NCT03677141
Clinical
Data Tier / Score
A · 62
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 9일 (5일 전)